Francesco Pierantoni

Publication Activity (10 Years)

Years Active: 2023-2023
Publications (10 Years): 4

Top Topics

Systematic Review

Renal Cell Carcinoma

Ejection Fraction

Top Venues

International journal of molecular sciences

Future science OA

This page only lists publications with an associated author ORCID identifier.

Publications

Marco Stellato, Sebastiano Buti, Marco Maruzzo, Melissa Bersanelli, Francesco Pierantoni, Ugo De Giorgi, Marilena Di Napoli, Roberto Iacovelli, Maria Giuseppa Vitale, Paola Ermacora, Andrea Malgeri, Brigida Anna Maiorano, Veronica Prati, Alessia Mennitto, Alessia Cavo, Matteo Santoni, Claudia Carella, Lucia Fratino, Giuseppe Procopio, Elena Verzoni, Daniele Santini
Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a). International journal of molecular sciences 24 (2) (2023)
Marco Stellato, Sebastiano Buti, Marco Maruzzo, Melissa Bersanelli, Francesco Pierantoni, Ugo De Giorgi, Marilena Di Napoli, Roberto Iacovelli, Maria Giuseppa Vitale, Paola Ermacora, Andrea Malgeri, Brigida Anna Maiorano, Veronica Prati, Alessia Mennitto, Alessia Cavo, Matteo Santoni, Claudia Carella, Lucia Fratino, Giuseppe Procopio, Elena Verzoni, Daniele Santini
Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a). International journal of molecular sciences 24 (2) (2023)
Marco Stellato, Sebastiano Buti, Marco Maruzzo, Melissa Bersanelli, Francesco Pierantoni, Ugo De Giorgi, Marilena Di Napoli, Roberto Iacovelli, Maria Giuseppa Vitale, Paola Ermacora, Andrea Malgeri, Brigida Anna Maiorano, Veronica Prati, Alessia Mennitto, Alessia Cavo, Matteo Santoni, Claudia Carella, Lucia Fratino, Giuseppe Procopio, Elena Verzoni, Daniele Santini
Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a). International journal of molecular sciences 24 (2) (2023)
Michele Dionese, Umberto Basso, Francesco Pierantoni, Eleonora Lai, Nicolò Cavasin, Elisa Erbetta, Salim Jubran, Giorgio Bonomi, Davide Bimbatti, Maruzzo Marco
Prognostic role of systemic inflammation indexes in metastatic urothelial carcinoma treated with immunotherapy. Future science OA 9 (7) (2023)